Inovio reports fda partial clinical hold for planned phase 2 / 3 trial of covid-19 vaccine candidate ino-4800

Inovio reports fda partial clinical hold for planned phase 2 / 3 trial of covid-19 vaccine candidate ino-4800.inovio pharma - partial clinical hold is not due to occurrence of any adverse events related to inovio's ongoing expanded phase 1 study of ino-4800.inovio pharmaceuticals inc - actively working to address fda's questions and plans to respond in october.inovio pharma - co, partners are continuing to prepare for a planned phase 2/3 trial of ino-4800, following resolution of fda's partial clinical hold.inovio - fda has additional questions about planned phase 2/3 trial of ino-4800, including cellectra 2000 delivery device to be used in trial.
INO Ratings Summary
INO Quant Ranking